<- Go Home
Liminal BioSciences Inc.
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. As of September 26, 2023, Liminal BioSciences Inc. was taken private.
Market Cap
N/A
Volume
165.00
Cash and Equivalents
EUR 19.3M
EBITDA
-EUR 31.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-EUR 15.0M
Profit Margin
3048.17%
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-EUR 32.0M
Return on Equity
141.94%
Return on Assets
-38.95
Cash and Short Term Investments
EUR 19.3M
Debt
EUR 1.2M
Equity
EUR 21.5M
Revenue
EUR 492.0K
Unlevered FCF
-EUR 26.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium